Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Journal for immunotherapy of cancer - 1 Jul 2022

Pires da Silva Ines, Zakria Danny, Ahmed Tasnia, Trojanello Claudia, Dimitriou Florentia, Allayous Clara, Gerard Camille, Zimmer Lisa, Lo Serigne, Michielin Olivier, Lebbe Celeste, Mangana Johanna, Ascierto Paolo Antonio, Johnson Douglas B, Carlino Matteo, Menzies Alexander, Long Georgina

Abstract excerpt

BACKGROUND: Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy is unknown. We aimed to determine the efficacy and safety of PD1 versus IPI +PD1 after BRAF/MEK inhibitors (BRAF/MEKi). METHODS: Patients with V600BRAF mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Ipilimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasms, Second Primary

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35798536
DOI: 10.1136/jitc-2022-004610
PMCID: PMC9263926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.PMID 35798536Read ↗

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read ↗

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.Semantic proximity Read ↗

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Semantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Semantic proximity Read ↗

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read ↗

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Semantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.Semantic proximity Read ↗

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.Semantic proximity Read ↗

Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.Semantic proximity Read ↗

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.